If you suffer from degenerative meniscal injury: fly to Medellín, Colombia and treat it with stem cells

Arthroscopic meniscectomy remains one of the most overprescribed surgeries in the world. degenerative meniscal injury is one of the most common reasons patients from the US, Europe, the Middle East and Latin America fly to Medellín every month looking for expanded mesenchymal stem cell therapy. They don't come chasing a discount — they come because at home their options end in anti-inflammatories, cortisone or surgery.

1. What is degenerative meniscal injury and why does it become chronic?

Degenerative meniscal injury is rarely an isolated mechanical issue. In most patients we evaluate it combines low-grade inflammation, progressive cartilage or tendon degeneration, and a dysregulated local immune response. That's why anti-inflammatories and cortisone injections give temporary relief but don't modify the disease — and often accelerate long-term joint damage.

The most common causes we see in clinic:

• Horizontal and complex degenerative tears of the medial meniscus.
• Symptomatic discoid meniscus.
• Partial post-traumatic tears without locking.
• Sequelae of previous meniscectomy with persistent pain.

2. How stem cells act on degenerative meniscal injury

We use allogeneic mesenchymal stem cells (MSCs) from umbilical cord, processed and expanded in a GMP-grade lab. In the meniscus these cells work through three mechanisms: immune modulation (they lower the chronic inflammatory environment), release of trophic factors (VEGF, TGF-β, IGF-1) and stimulation of endogenous repair of cartilage, tendon or disc.

In degenerative tears without locking, evidence shows intra-articular MSCs improve symptoms at least as well as arthroscopic meniscectomy, without accelerating osteoarthritis.

3. Are you a candidate with this degenerative meniscal injury presentation?

You likely are if you present with:

• Persistent meniscus pain for more than 3 months, with or without previous injections.
• Imaging showing mild to moderate degeneration (not end-stage destruction).
• A desire to avoid or delay surgery and commit to rehabilitation.
• Good overall health (no active infection, no active cancer).

It's not a good indication if:

• True mechanical locking with inability to extend the knee.
• Displaced 'bucket handle' tear.
• Associated grade IV OA with severe deformity.

4. Diagnostic studies we need

Before defining a protocol for your degenerative meniscal injury, we request the following studies (or coordinate them in Medellín within 24–48 h):

• Knee MRI (fundamental).
• Weight-bearing X-ray.
• Clinical assessment of stability and alignment.

5. How we apply stem cells for degenerative meniscal injury

Ultrasound-guided intra-articular application, with complementary IV dose and peptides.

The complete protocol usually combines:

• Local ultrasound- or fluoroscopy-guided application by Dr. Joaqui.
• Systemic IV MSC dose to modulate whole-body inflammation.
• Regenerative peptides (BPC-157, TB-500, CJC/Ipamorelin depending on case).
• Biomechanical rehab post-application and personalized supplementation.

6. Expected results and timeline

• Weeks 2–6: clear drop in the inflammatory component; resting pain usually improves first.
• Months 2–3: better range of motion and load tolerance.
• Months 3–6: regenerative effect consolidates; a booster dose is evaluated.
• 60–85% of properly selected patients report significant pain reduction at 12 months.

7. Treatment cost for degenerative meniscal injury in Medellín

Typical range for integrated degenerative meniscal injury care: USD 4,500–10,500, depending on whether the plan combines local injection, IV dose, peptides and/or exosomes. Includes consultations, cells with lot certificate, applications, control labs and 6 months of telemedicine follow-up.

In the US, comparable protocols cost between USD 15,000 and 45,000 and rarely include structured follow-up.

8. What the trip to Medellín looks like

1. Initial teleconsult (30–45 min) with Dr. Joaqui.
2. You share recent imaging and labs of your meniscus.
3. You receive a personalized protocol, schedule and closed budget.
4. We coordinate medical hotel, transfers and translator if needed.
5. Typical stay in Medellín: 5–8 días / days with 2–3 application sessions.
6. You go home with a written rehab protocol and active telemedicine for 6 months.

9. Safety and traceability

Colombia regulates cell therapy through INVIMA and institutional ethics committees. Every cell lot we use for your degenerative meniscal injury includes reports of viability > 90%, MSC phenotype (CD73⁺, CD90⁺, CD105⁺; CD34⁻, CD45⁻), sterility and full donor traceability.

10. Real testimonial from a patient with degenerative meniscal injury

"I was scheduled for meniscectomy. I chose stem cells and three months later I was back to recreational soccer, pain- and lock-free."

11. Frequently asked questions

About Dr. Joaqui

Dr. William Joaqui is one of the leading references in regenerative medicine and stem cell therapy in Latin America. He has developed integrated protocols with MSCs, exosomes, peptides, NAD+ and biomechanical rehab for joint, tendon and spine conditions. He personally attends every international patient from the initial teleconsult.